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The resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine (SP) is an emerging public health
threat. Resistance to these drugs is associated with point mutations in the genes encoding dihydropteroate
synthase (DHPS) and dihydrofolate reductase (DHFR). We describe here an assay using real-time PCR and
sequence-specific probes that detects these mutations. Using DNA from plasmids, cultured strains, and clinical
samples, real-time PCR could distinguish four DHPS polymorphisms (codons 437, 540, 581, and 613) and three
DHFR polymorphisms (codons 51, 59, and 108). This assay is rapid and sensitive, with a detection limit of 10
copies in most cases. This assay is amenable to large-scale studies of drug resistance.
Malaria is a major public health threat, causing millions of
deaths per year. One of the greatest challenges in the control
of malaria is drug resistance, which has contributed to its
reemergence and spread (23). At present, chloroquine resis-
tance in Plasmodium falciparum is nearly universal; because of
chloroquine resistance, five African countries have switched to
sulfadoxine-pyrimethamine (SP) as their first-line antimalarial
agent (23). However, resistance to SP is spreading.
Sulfadoxine and pyrimethamine inhibit dihydropteroate syn-
thase (DHPS) and dihydrofolate reductase (DHFR), respec-
tively, which are two enzymes involved in folate biosynthesis.
SP resistance is conferred by single nucleotide changes in ei-
ther enzyme, and increases as mutations accumulate (refer-
ence 18 and references therein). For DHFR, the mutations
Arg-50, Ile-51, Arg-59, and Asn-108 have been strongly asso-
ciated with in vitro and in vivo resistance and are correlated
with SP usage (9, 11, 14, 19). Mutations in DHPS (Ala-436,
Phe-436, Gly-437, Lys-540, Gly-581, Thr-613, and Ser-613)
have also been associated with in vitro and in vivo resistance,
although they have a weaker relationship with SP usage than
DHFR mutations (2, 9, 11, 15, 19, 21). Other DHFR polymor-
phisms are more closely associated with cycloguanil resistance
(Val-16 and Thr-108) (16).
Surveillance for antimalarial drug resistance is usually done
by using in vitro or in vivo methods. In vitro methods involve
the culturing of malaria parasites, which is difficult and re-
quires skilled technicians and tissue culture facilities. In vivo
methods require patients to be monitored for at least 14 days,
which is often challenging in field conditions. Thus, new sur-
veillance tools are needed. Numerous studies, by using stan-
dard PCR methods, have shown that DHPS and DHFR mu-
tations are closely associated with SP resistance. However, the
usefulness of these assays is restricted due to difficulty, cost,
high risk for contamination, and the inability to pick up low-
prevalence genotypes in a mixed sample (4). Real-time PCR,
on the other hand, is simpler and less prone to contamination.
The purpose of the present study was to develop a real-time
PCR assay for DHPS and DHFR mutations.
Real-time PCR minor groove binding (MGB) probes pro-
vide a relatively inexpensive and sensitive way to detect single-
nucleotide polymorphisms (SNPs) in a large number of sam-
ples (1, 13). MGB probes are designed to hybridize to an
internal region of the PCR amplicon, thereby providing an-
other level of specificity beyond the site-specific primers. When
the Taq DNA polymerase cleaves the probe from the 5 end,
the fluorophore is released from the quencher, allowing it to
fluoresce. The increase in fluorescence over time can be mea-
sured by using a real-time PCR thermocycler. Single base dif-
ferences between MGB probes and DNA cause the melting
temperature to decrease significantly, which decreases the ef-
ficiency of probe hybridization (12, 13). Allelic discrimination
is achieved by putting in competition two probes complemen-
tary to wild-type and mutant alleles, which are attached to
different fluorophores (13). The risk for contamination is much
lower in this technique because there is no transfer of material
between the addition of the DNA and the acquisition of the
results (20). This technique has been used for allelic discrim-
ination in humans, and a similar technique has been used to
identify alleles that confer drug resistance in bacteria (8, 10,
13).
The impending loss of SP effectiveness in Africa, due to drug
resistance, could have calamitous consequences. Partnering SP
with another antimalarial agent, such as artesunate, might pre-
serve SP effectiveness by delaying the onset of SP resistance. In
order to measure the effects of combination chemotherapy on
the development of SP resistance in Africa, we attempted to
develop real-time PCR assays for the three DHFR polymor-
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phisms (Ile-51, Arg-59, and Asn-108) and five DHPS polymor-
phisms (Ala-436, Gly-437, Lys-540, Gly-581, and Ser-613) re-
ported from Africa.
MATERIALS AND METHODS
DNA. Six DHPS plasmids (MRA-189 through MRA-194) and five DHFR
plasmids (MRA-195 through MRA-199) contained in Escherichia coli were ob-
tained from the Malaria Reagent Repository Resource (http://www.malaria
.mr4.org/and references therein), containing the wild-type sequences and the
most important mutations for each gene. The E. coli clones were grown on
Luria-Bertani medium (1% tryptone, 0.5% yeast extract, 1.5% agarose in deion-
ized H2O) with 50 g of ampicillin/ml. The plasmids were extracted and purified
by using the Promega Wizard Plus Minipreps DNA purification system (Pro-
mega, Madison, Wis.). P. falciparum strain 3D7 parasites were kindly provided by
Jesse Kwiek, Duke University. DNA was extracted by using the QIAamp DNA
minikit (Qiagen, Hilden, Germany). DNA from six strains of P. falciparum (Dd2,
HB3, W2, FCR3, K1, and VI/S) was obtained from the Malaria Reagent Re-
pository Resource.
Clinical samples of malaria parasites were obtained from a subgroup of preg-
nant women enrolled in a study investigating the effect of maternal malarial
infection on mother-to-child transmission of human immunodeficiency virus
(HIV). Details of the study, which commenced in December 2000, have been
reported elsewhere (14a). Briefly, consent was sought from women in their late
third trimester of pregnancy before the onset of active labor. Peripheral blood
samples were drawn to screen for malaria by using thick-blood-smear microscopy
and to detect HIV infection by using rapid antibody tests. All HIV-infected
women and a subset of HIV-uninfected were enrolled in that study. For the
present study, 24 clinical samples were genotyped: 21 from HIV-infected women
with malaria, one from a parasitemic HIV-uninfected woman, and two control
samples from HIV-infected women who were not parasitemic. With the excep-
tion of one HIV-infected woman, all women reported taking at least one dose of
SP during the antenatal period.
Peripheral blood samples were centrifuged, and the plasma and packed-cell
fractions were stored at 80°C. Subsequently, frozen packed cells were thawed,
and a few drops were transferred onto filter paper. These were shipped to the
University of North Carolina at Chapel Hill, where DNA extraction was per-
formed by using the QIAamp DNA minikit (Qiagen, Hilden, Germany).
Primers and probes. All primers and probes in the present study were de-
signed by using Primer Express software (Applied Biosystems, Courtaboeuf,
France), with the defaults of the program, except that the minimum %GC
content was lowered to 20% due to the AT-rich nature of the P. falciparum
genome. P. falciparum strain 3D7 sequences for DHFR (accession number
AF248537) and DHPS (accession number AF250167) were used in probe and
primer design. When we designed the primers and probes, we assumed that all
codons within the amplicon were wild type except for the SNP of interest. All
primers were synthesized by Qiagen. The probes were synthesized by Applied
Biosystems with the fluorophores FAM (6-carboxyfluorescein) linked to the 5
position of all wild-type probes and VIC (chemical name not released by Applied
Biosystems) linked to the 5 position of all mutant probes. A nonfluorescent
TABLE 1. Real-time primer and probe sequences and optimal concentrations
Target Oligonucleotide (5 3 3)a Final concn (nM) Detection limit(copies/reaction)




DHFR-59 F: Same as DHFR-51 300
R: Same as DHFR-51 500
WTP: AATATTTTTGTGCAGTTACA 100
MP: TGAAATATTTTCGTGCAGTTA 10








DHPS-436 Primers and wild-type probe same as DHPS-437
MP: AGAATCCGCTGTC NSb








DHPS-613 F: TGGATTAGGATTTGCGAAGAAAC 500
R: GTTGTGTATTTATTACAACATTTTGATCATTC 300
WTP: ATTTATTGCCCATTGCAT 10
MP: AGATTTATTTCCCATTGCA (serine) 10
MP: AGATTTATTACCCATTGCA (threonine) NS
a The SNP is underlined in the probes. F, forward primer; R, reverse primer; WTP, wild-type probe; MP, mutant probe.
b NS, not successful.
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quencher and a minor groove binder were linked to the 3 ends of all probes
(chemical names not released by Applied Biosystems).
Real-time PCR. PCRs were carried out in duplicate in a 25-l final volume
containing 12.5 l of Universal PCR Master Mix, 5 l of DNA, forward and
reverse primers at various concentrations, and both mutant and wild-type probes
at a final concentration of 200 nM. Optimal primer concentrations were deter-
mined by running the reactions with all combinations of the forward and reverse
probes at 300, 500, and 900 nM (Table 1). All reactions were run on an ABI
Prism 7000 sequence detection system (Applied Biosystems) with the default
settings; each sample was initially denatured at 95°C for 10 min and cycled 40
times, with each cycle consisting of 95°C for 15 s and 60°C for 60 s.
Data were transferred into Microsoft Excel version 2002, where the baseline
(minimum) fluorescence was subtracted and replicates were averaged. To deter-
mine the detection limit for the wild-type and mutant probes, 10-fold dilutions of
the relevant plasmids were run in triplicate. The detection limit was taken as the
lowest copy number at which the standard deviation of the fluorescence of the
wild-type and mutant genotype did not overlap. To assess the compatibility of
this assay with mixed samples, two primer-probe sets (DHFR-51 and DHFR-59)
were run with DNA from different proportions (0:1, 1:9, 2:8, 5:5, 8:2, 9:1, and 1:0)
of wild-type and mutant plasmids. A total of 10,000 copies of plasmid DNA was
used in each reaction.
To determine the specificity of the primer-probe sets and to ensure their
compatibility with genomic DNA, seven strains of P. falciparum (3D7, Dd2,
FCR3, HB3, K1, VI/S, and W2) were genotyped by using real-time PCR. The
DHFR and DHPS genotypes of these strains, presented in Table 2, have been
reported elsewhere (3, 6, 7, 18, 22). Real-time PCR was performed as described
above except that only 1 l of DNA was used per reaction. The genotype was
determined by visually comparing the change in fluorescence of the wild-type and
mutant probes.
Validation of method by genotyping clinical samples. The first step in geno-
typing the clinical samples involved the use of real-time PCR to detect the lactate
dehydrogenase (ldh) gene under the conditions described previously (17). Serial
dilutions of P. falciparum 3D7 DNA at a known concentration were run on the
same plate as the clinical samples. A standard curve of the 3D7 DNA was
constructed and used to extrapolate the DNA concentration of the clinical
samples. P. falciparum DNA was not detected in the two control samples from
nonparasitemic women and therefore were not processed further. The remaining
22 samples were genotyped by real-time PCR with the optimal primer and probe
concentrations (Table 1). The amount of DNA added per reaction varied (1 to
3 l) depending on the detection limit of the primer-probe set and the concen-
tration of the sample. Samples of low concentration were run for 45 cycles
instead of 40 cycles. Each plate contained DNA from P. falciparum strains at
relevant concentrations to act as wild-type and mutant controls.
The genotype was determined by comparing the cycle threshold (CT) values of
the wild-type and mutant probe for each sample. The CT is the number of PCR
cycles needed before the fluorescent signal surpasses a certain threshold (usually
20 to 40% of maximum). The more DNA of a specific genotype, the smaller the
CT for that genotype-specific probe. For example, a sample was deemed to be
wild type when the wild-type probe CT was less than the mutant probe CT and
the difference was similar to that seen with the wild-type plasmid DNA. A sample
was considered to be mixed when the CT’s of both wild-type and mutant probes
were closer and intermediate between the patterns seen for pure and wild-type
plasmid DNA.
Five clinical samples were chosen to be sequenced based on the following
criteria. (i) Real-time results were available for all seven SNPs. (ii) Both wild-
type and mutant genotypes were included, when possible. (iii) If the sample was
mixed, a dominant genotype could be distinguished from real-time PCR (which
eliminated three samples from consideration).
Sequencing. The five clinical samples were amplified with the same primers as
in the MGB real-time PCR assay. Reactions were carried out in 25-l final
volume containing 12.5 l of SYBR Green Master Mix, 1 l of DNA, and
forward and reverse primers at 300 nM. All reactions were run on an ABI Prism
7000 sequence detection system (Applied Biosystems) with the default settings
with the dissociation step added at 60°C. The dissociation curves were examined
to ensure that each reaction contained only one product. The resulting amplicon
was purified by using CentriSpin-10 columns (Princeton Separations, Adelphia,
N.J.). Sequencing was performed at the University of North Carolina Sequencing
Core by using the ABI Prism BigDye terminator cycle sequencing ready reaction
kit (Applied Biosystems).
RESULTS
Real-time PCR was both sensitive and specific for P. falci-
parum DHFR and DHPS genetic polymorphisms. The reaction
conditions were effective for a wide range of P. falciparum
DNA concentrations and had detection limits ranging from 10
to 1,000 copies (Table 1).
For the seven polymorphisms shown in Fig. 1, the wild-type
probe generated fluorescence with the wild-type sequence but
TABLE 2. DHFR and DHPS genotypes for P. falciparum strains and clinical samples as determined by sequencinga
Strain or sample
Amino acid at:
DHFR codon: DHPS codon:
51 59 108 436 437 540 581 613
Strains
3D7 Asn Cys Ser Ser Gly Lys Ala Ala
Dd2 Ile Arg Asn Phe Gly Lys Ala Ser
HB3 Asn Cys Asn Ser Ala Lys Ala Ala
W2 Ile Arg Asn Phe Gly Lys Ala Ser
FCR3 Asn Cys Thr Ser Ala Lys Ala Ala
K1 Asn Arg Asn Ser Gly Lys Gly Ala
VI/S Ile Arg Asn Phe Gly Lys Ala Thr
Clinical samples
CS1318 Ile Arg Asn Ser Ala Lys* Ala Ala
CS1338 Ile* Arg Asn Ser Gly Glu Ala* Ala
CS1452 Ile Arg Asn Ser Ala* Glu Gly* Ala
CS1648 Ile Cys Asn Ser Gly Glu Ala Ala
CS1915 Ile* Arg Asn Ser Gly Glu Ala Ala
Reference
WT Asn Cys Ser Ser Ala Lys Ala Ala
M Ile Arg Asn/Thr Ala/Phe Gly Glu Gly Ser/Thr
a The last two rows portray the wild-type (WT) and mutant (M) genotypes for each polymorphism. See the text for citations. Clinical samples that were identified
as mixed with real-time PCR are indicated by an asterisk.
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not the mutant sequence, while the mutant probe generated
fluorescence with the mutant sequence but not the wild-type
sequence. No amplification was ever seen in the absence of
template (data not shown).
Background fluorescence (wild-type probe with mutant se-
quence and vice versa) was minimal, except in the case of the
DHFR wild-type (Cys-59) probe. However, this background
reaction did not prevent genotype determination, since the
wild-type sequence still clearly amplified more rapidly than the
mutant sequence. The original batch of the Cys-59 probe had
a weak signal but provided sufficient discriminating ability.
Subsequent batches of Cys-59 wild-type probe from Applied
Biosystems had a much stronger signal and more background
binding. However, the discriminating ability was similar to the
original batch (data not shown).
Attempts to distinguish polymorphisms at DHPS-436 were
unsuccessful. Real-time PCR was successful in determining the
genotype of the P. falciparum strains for DHFR-51, DHFR-59,
DHPS-540, and DHPS-581. For DHFR-108, the probe was
designed to detect the asparagine mutant. However, the mu-
tant probe also picked up the Thr-108 mutant, though the CT
value was greater than that for Asn-108. Similarly, the DHPS-
613 mutant probe, designed to identify the Ser-613 mutation,
also bound to the Thr-613 mutation. However, in this case the
CT values for the mutant probe were similar for both Ser-613
and Thr-613, and therefore they could not be distinguished. In
both cases, wild type could be distinguished from mutant se-
quences. The genotyping of DHPS-437 was successful in the
presence of Ser-436. There was no binding of the wild-type or
mutant probe for DHPS-437 in the presence of the Ala-436
and Phe-436 mutations.
For two of the loci (DHFR-51 and DHFR-59), various mix-
tures of wild-type and mutant plasmids were prepared and
then PCR amplified. In all cases, a mixture could be differen-
tiated from a pure sample if the minor component was present
at 10% (Fig. 2).
This method was validated with clinical samples. Complete
DHFR genotypes were determined by using real-time PCR for
all 22 samples taken from parasitemic women. An example of
the real-time amplification of a clinical sample is shown in Fig.
3. In regards to DHPS, 21 samples were fully genotyped; the
DHPS-540 genotype could not be ascertained for one sample.
FIG. 1. Real-time PCR detection of P. falciparum genotypes. Plas-
mid DNA containing wild-type and mutant template DNA (as labeled)
were amplified with mixtures of wild-type probe (FAM labeled [solid
line]) and mutant probe (VIC labeled [broken line]). Relative fluores-
cence was calculated by subtracting the minimal fluorescence from
each value.
FIG. 2. Real-time PCR genotyping of a mixed genotype sample.
Various mixtures of wild-type and mutant plasmid DNA were ampli-
fied. The results for the 51 VIC probe are presented as the averages of
three replicates from which the minimal fluorescence has been sub-
tracted. The solid line represents a 100% mutant sample. The gray line
represents a 10% mutant and a 90% wild-type sample. The broken line
represents a 100% wild-type sample.
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The five selected clinical samples were successfully sequenced
for all seven loci. For the three DHFR loci and four DHPS
loci, there was a 100% concordance of the dominant genotype
between sequencing and real-time PCR (Table 2). Sequencing
was unable to detect mixed infections that were identified by
using real-time PCR.
DISCUSSION
We describe a real-time PCR assay to detect polymorphisms
associated with drug resistance in P. falciparum. We could
successfully discriminate between wild-type and resistant al-
leles in seven of the eight loci important in Africa.
As a surveillance tool, real-time PCR has certain advantages
over classical PCR. First, the assay is rapid and can reliably
distinguish between two alleles after a single 3-h experiment.
There is no need to run gels after the reaction. Second, the risk
of contamination is far lower than with nested PCR because it
is a closed-tube reaction. Third, the assay can be automated
and processed in a high-throughput fashion. The initial cost of
real-time PCR (consisting of buying the actual machine and
optimizing the assay) is higher than normal PCR and may not
be available in all countries where malaria is endemic. How-
ever, part of this cost could be made up if used for high-
throughput processing since reagents for a single reaction cost
between $0.40 and $2 (U.S. dollars).
Recently, a fluorogenic PCR assay using FRET probes was
developed to genotype codons 50 to 60 of DHFR in P. falci-
parum (5). This technique has an advantage of low risk of
contamination similar to that of the assay we describe in the
present study. However, it has yet to be expanded to detect the
other important mutations associated with drug resistance.
There are several limitations to the real-time PCR system
described here. The most serious deficiency is its inability to
distinguish alleles at position 436, and alleles at 437 when there
is a mutation at the 436 position. However, the 436 mutations
are rare in Africa and appear not to be involved in the “quin-
tuple mutants” (Asn-108, Ile-51, and Arg-59 in DHFR and
Gly-437 and Glu-540 in DHPS) that are especially important in
Africa (18). Also, although real-time PCR can theoretically
distinguish three or more alleles, we were not able to accom-
plish this at DHFR positions 108 and 613. Although we can
distinguish the wild type from mutants at DHFR position 108,
we could not distinguish between Asn-108, associated with SP
resistance, and Thr-108, associated with cycloguanil resistance.
Thus, further study is needed to enable the detection of these
other polymorphisms. In addition, it should be noted that the
detection limit differs among the primer-probe sets. This could
potentially lead to an under-representation of certain geno-
types. Nevertheless, given the advantages of this method, real-
time PCR measurement of seven DHFR and DHPS polymor-
phisms could serve as a useful tool for the surveillance of
SP-resistant malaria.
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